Uridine triphosphate

Drug Profile

Uridine triphosphate

Alternative Names: INS 316; INS 316 Diagnostic; KRN-316; Prolucin; UTP

Latest Information Update: 06 Jun 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Inspire Pharmaceuticals; Kirin Brewery
  • Class Diagnostic agents; Expectorants; Nucleosides; Small molecules
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bronchitis; Cystic fibrosis; Lung cancer; Primary ciliary dyskinesia

Most Recent Events

  • 01 Jul 2003 Inspire is analysing phase III results with the aim to decide whether to terminate or continue the programme
  • 15 Nov 2001 A study has been added to the Diagnostic Agents therapeutic trials and adverse events sections
  • 28 Jun 2001 Genentech is no longer collaborating with Inspire Pharmaceuticals on pyrimidine Y2 agonist programmes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top